Related Experiment Video

Updated: Aug 13, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

[Inhibitory effect of AG1109 on recombinant human protein kinase CK2 holoenzyme]

Xin-guang Liu1, Nian-ci Liang

  • 1Institute of Biochemistry & Molecular Biology, Guangdong Medical College, Zhanjiang 524023, P. R. China. xgliu@gdmc.edu.cn

AI Zheng = Aizheng = Chinese Journal of Cancer
|December 14, 2002
PubMed
Abstract

Insights

Tyrphostin AG1109 effectively inhibits protein kinase CK2 (casein kinase 2), a cancer-associated enzyme. This study demonstrates AG1109 as a potent CK2 inhibitor, paving the way for new cancer therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Protein kinase CK2 (casein kinase 2) is a serine/threonine kinase.
  • CK2 is frequently upregulated in various cancers and acts as an oncogene.
  • Targeting CK2 offers a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To investigate the direct effects of tyrphostin AG1109 on recombinant human protein kinase CK2 holoenzyme.
  • To determine the kinetic properties of AG1109 inhibition on CK2.
  • To evaluate AG1109 as a potential CK2 inhibitor for cancer therapy.

Main Methods:

  • Recombinant human CK2 alpha and beta subunits were engineered, expressed, and purified.
  • CK2 holoenzyme was reconstituted to achieve maximum biological activity.
  • Enzyme activity was measured by 32P incorporation from [gamma-32P]ATP or [gamma-32P]GTP.

Main Results:

  • Reconstituted CK2 exhibited properties consistent with native CK2 and was independent of second messengers.
  • AG1109 strongly inhibited holoenzyme activity with an IC50 of 9.7 µmol/L, outperforming known inhibitors DRB and A3.
  • Kinetic analysis revealed AG1109 acts as a mixed-type inhibitor (predominantly competitive) with GTP and noncompetitively with casein.

Conclusions:

  • AG1109 is a potent inhibitor of recombinant human protein kinase CK2 holoenzyme.
  • Recombinant CK2 can serve as a valuable molecular target for developing novel CK2 inhibitors.
  • These findings support the development of AG1109 or similar compounds for cancer treatment.

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting10:08

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...